NEW YORK (GenomeWeb) – Caris Life Sciences will be using IBM's technical computing and storage technology to bolster its ability to molecularly profile cancer patients and provide information that oncologists can use to personalize care.
Working with IBM and its business partner Re-Store, a company that designs and supports digital infrastructures, Caris has developed a system that enables analysis of complex molecular profiling data. "With the support of IBM technical computing and software defined storage technology, Caris can now make recommendations on 55 potentially actionable drug to molecular target associations as a result of being able to profile both genomic and proteomic data," the firm said in a statement.
This represents "a significant increase" for Caris, which is able to currently make 19 such recommendations using just patients' genomic information. With IBM's storage systems, Caris is also able to access and process large sets of data at a much faster time frame.
Caris claims to have tested more than 65,000 cancer patients for 70 different molecular markers through its profiling services. The markers are associated with response to 55 drugs approved by the US Food and Drug Administration and numerous investigational agents.